-- AstraZeneca has shelved a plan to build a vaccine manufacturing plant in Speke, near Liverpool, valued at 450 million pounds ($558.7 million), after months of talks with British government officials about state investment, the Financial Times reports, citing a company statement and unnamed sources.
-- Keir Starmer's Labour government last year sought to reduce the amount of state support to 40 million pounds from 90 million pounds, but U.K. officials last month put forward an offer significantly higher than 40 million pounds, the FT says, citing unnamed sources.
-- The final offer was one of the factors influencing its decision to ditch the plan, AstraZeneca said, according to the FT.
Full story: https://tinyurl.com/5yxveb6e
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
January 31, 2025 11:07 ET (16:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。